Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes

Epigenetic gene regulation is a critical process controlling differentiation and development, the malfunction of which may underpin a variety of diseases. In this article, we review the current landscape of small-molecule epigenetic modulators including drugs on the market, key compounds in clinical trials, and chemical probes being used in epigenetic mechanistic studies. Hit identification strategies for the discovery of small-molecule epigenetic modulators are summarized with respect to writers, erasers, and readers of histone marks. Perspectives are provided on opportunities for new hit discovery approaches, some of which may define the next generation of therapeutic intervention strategies for epigenetic processes.

[1]  Stephan Beck,et al.  The methylome: approaches for global DNA methylation profiling. , 2008, Trends in genetics : TIG.

[2]  John Kuriyan,et al.  The origin of protein interactions and allostery in colocalization , 2007, Nature.

[3]  Dinshaw J. Patel,et al.  Multivalent engagement of chromatin modifications by linked binding modules , 2007, Nature Reviews Molecular Cell Biology.

[4]  Baoguang Zhao,et al.  Design, synthesis and selection of DNA-encoded small-molecule libraries. , 2009, Nature chemical biology.

[5]  M. Begemann,et al.  Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective , 2007, Stem cells.

[6]  Jacqueline Cherfils,et al.  Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein–protein complexes , 2007, Proceedings of the National Academy of Sciences.

[7]  T. Heightman,et al.  Inhibition of Histone Demethylases by 4‐Carboxy‐2,2′‐Bipyridyl Compounds , 2011, ChemMedChem.

[8]  T. Kundu,et al.  Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.

[9]  Burkhard Rost,et al.  Protein–Protein Interaction Hotspots Carved into Sequences , 2007, PLoS Comput. Biol..

[10]  C. Allis,et al.  Chromatin remodeling and cancer, Part I: Covalent histone modifications. , 2007, Trends in molecular medicine.

[11]  K. Kish,et al.  Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. , 2011, The Biochemical journal.

[12]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[13]  R. Eglen,et al.  Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome , 2011, Journal of biomolecular screening.

[14]  S. Pang,et al.  Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). , 2008, Bioorganic & medicinal chemistry letters.

[15]  Jonathan C. Fuller,et al.  Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.

[16]  Nobuyoshi Sugaya,et al.  Assessing the druggability of protein-protein interactions by a supervised machine-learning method , 2009, BMC Bioinformatics.

[17]  A. Mills.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins , 2010, Nature Reviews Cancer.

[18]  G. Petsko,et al.  Multiple solvent crystal structures: probing binding sites, plasticity and hydration. , 2006, Journal of molecular biology.

[19]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[20]  D. Patel,et al.  Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex , 2006, Nature Structural &Molecular Biology.

[21]  M. Duvic,et al.  Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.

[22]  Chao Xu,et al.  Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2) , 2010, Proceedings of the National Academy of Sciences.

[23]  D. Baker,et al.  A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. García,et al.  Functional and quantitative proteomics using SILAC in cancer research , 2008 .

[25]  Min Gyu Lee,et al.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. , 2006, Chemistry & biology.

[26]  C. Arrowsmith,et al.  Fluorescence-Based Methods for Screening Writers and Readers of Histone Methyl Marks , 2012, Journal of biomolecular screening.

[27]  F. Sams-Dodd,et al.  Drug discovery: selecting the optimal approach. , 2006, Drug discovery today.

[28]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[29]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[30]  A. Simeonov,et al.  Methods for Activity Analysis of the Proteins that Regulate Histone Methylation , 2011, Current chemical genomics.

[31]  M. Cosgrove,et al.  Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide* , 2008, Journal of Biological Chemistry.

[32]  J. Snyder,et al.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 , 2009, Nature Structural &Molecular Biology.

[33]  S. Lanouette,et al.  Structural and biochemical insights into MLL1 core complex assembly. , 2011, Structure.

[34]  R. Roeder,et al.  HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. , 2000, Molecular cell.

[35]  T. Berg.  Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[36]  Ming-Ming Zhou,et al.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. , 2011, Chemistry & biology.

[37]  E. Li,et al.  Epigenetics and Disease , 2011 .

[38]  S. Knapp,et al.  Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.

[39]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[40]  M. Bunnage.  Getting pharmaceutical R&D back on target. , 2011, Nature chemical biology.

[41]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[42]  C. Allis,et al.  Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. , 2007, Trends in molecular medicine.

[43]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Chung,et al.  Progress in the Discovery of Small-Molecule Inhibitors of Bromodomain–Histone Interactions , 2011, Journal of biomolecular screening.

[45]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[46]  Philip J. Hajduk,et al.  Fragment-based lead discovery: challenges and opportunities , 2011, J. Comput. Aided Mol. Des..

[47]  K. Parnell,et al.  Epigenetic Drug Discovery , 2012, Journal of biomolecular screening.

[48]  S. Schreiber,et al.  A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. , 2011, Journal of the American Chemical Society.

[49]  S. Baylin,et al.  Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes , 2009, Clinical Cancer Research.

[50]  W. Sippl,et al.  Computer- and structure-based lead design for epigenetic targets. , 2011, Bioorganic & medicinal chemistry.

[51]  Ozlem Keskin,et al.  HotSprint: database of computational hot spots in protein interfaces , 2007, Nucleic Acids Res..

[52]  Paul A Clemons,et al.  Complex phenotypic assays in high-throughput screening. , 2004, Current opinion in chemical biology.

[53]  J. J. Jehring.  The productivity crisis , 1967 .

[54]  David C Fry,et al.  Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.

[55]  R. Jirtle,et al.  Environmental epigenomics and disease susceptibility , 2007, Nature Reviews Genetics.

[56]  Y. Dragan,et al.  What do we need to know prior to thinking about incorporating an epigenetic evaluation into safety assessments? , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[57]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[58]  J. Medina-Franco,et al.  Advances in the computational development of DNA methyltransferase inhibitors. , 2011, Drug discovery today.

[59]  Zhengwei Peng,et al.  Druggability assessment of protein-protein interfaces. , 2011, Future medicinal chemistry.

[60]  M. Mann,et al.  A SILAC-based DNA protein interaction screen that identifies candidate binding proteins to functional DNA elements. , 2009, Genome research.

[61]  R. Schneider-Stock,et al.  Histone deacetylase inhibitors: signalling towards p21cip1/waf1. , 2007, The international journal of biochemistry & cell biology.

[62]  P. Trojer,et al.  Target-based approach to inhibitors of histone arginine methyltransferases. , 2007, Journal of medicinal chemistry.

[63]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[64]  Yong Chen,et al.  Crystal structure of human histone lysine-specific demethylase 1 (LSD1) , 2006, Proceedings of the National Academy of Sciences.

[65]  Richard M. Jackson,et al.  Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..

[66]  Anton V. Bieliauskas,et al.  Isoform-Selective Histone Deacetylase Inhibitors , 2008 .

[67]  Roberto Sanchez,et al.  The role of human bromodomains in chromatin biology and gene transcription. , 2009, Current opinion in drug discovery & development.

[68]  A. Wettstein.  Fortschritte der Arzneimittelforschung , 1960, Experientia.

[69]  Sean D. Taverna,et al.  How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers , 2007, Nature Structural &Molecular Biology.

[70]  N. Avvakumov,et al.  The MYST family of histone acetyltransferases and their intimate links to cancer , 2007, Oncogene.

[71]  Herbert Edelsbrunner,et al.  Interface surfaces for protein-protein complexes , 2004, RECOMB.

[72]  Peter A. Jones,et al.  Targeting DNA methylation for epigenetic therapy. , 2010, Trends in pharmacological sciences.

[73]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[74]  N. Keen,et al.  Structural basis of substrate methylation and inhibition of SMYD2. , 2011, Structure.

[75]  R. Higgs,et al.  Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution , 2009, Expert opinion on drug discovery.

[76]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[77]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[78]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[79]  S. Pang,et al.  Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies. , 2009, Bioorganic & medicinal chemistry letters.

[80]  J. Buggy,et al.  Isoform-specific histone deacetylase inhibitors: the next step? , 2009, Cancer letters.

[81]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[82]  E. Whitelaw,et al.  Transgenerational epigenetic inheritance in health and disease. , 2008, Current opinion in genetics & development.

[83]  Makoto Hasegawa,et al.  Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. , 2010, Journal of medicinal chemistry.

[84]  Matthieu Schapira,et al.  Structural genomics of histone tail recognition , 2010, Bioinform..

[85]  Edwin Smith,et al.  The Language of Histone Crosstalk , 2010, Cell.

[86]  F. J. Luque,et al.  Binding site detection and druggability index from first principles. , 2009, Journal of medicinal chemistry.

[87]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Albert J R Heck,et al.  Revealing promiscuous drug-target interactions by chemical proteomics. , 2009, Drug discovery today.

[89]  M. Szyf.  Epigenetics, DNA methylation, and chromatin modifying drugs. , 2009, Annual review of pharmacology and toxicology.

[90]  A. Jeltsch,et al.  C5‐DNA Methyltransferase Inhibitors: From Screening to Effects on Zebrafish Embryo Development , 2011, Chembiochem : a European journal of chemical biology.

[91]  J. Manfredi,et al.  Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. , 2006, Chemistry & biology.

[92]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[93]  R A Rifkind,et al.  Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Steven A Carr,et al.  Identifying the proteins to which small-molecule probes and drugs bind in cells , 2009, Proceedings of the National Academy of Sciences.

[95]  M. Schapira,et al.  Finding Inspiration in the Protein Data Bank to Chemically Antagonize Readers of the Histone Code , 2010, Molecular informatics.

[96]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[97]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[98]  Sandor Vajda,et al.  Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. , 2007, Journal of medicinal chemistry.

[99]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Tatjana Buklijas,et al.  Epigenetic mechanisms that underpin metabolic and cardiovascular diseases , 2009, Nature Reviews Endocrinology.

[101]  W. Sippl,et al.  Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. , 2011, Bioorganic & medicinal chemistry.

[102]  Min Gyu Lee,et al.  An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation , 2005, Nature.

[103]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[104]  S. Baylin,et al.  Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes , 2007, Proceedings of the National Academy of Sciences.

[105]  P. Workman,et al.  A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation , 2007, Molecular Cancer Therapeutics.

[106]  John L Rinn,et al.  RNA traffic control of chromatin complexes. , 2010, Current opinion in genetics & development.

[107]  N. Reich,et al.  DNA cytosine C5 methyltransferase Dnmt1: catalysis-dependent release of allosteric inhibition. , 2005, Biochemistry.

[108]  F. Forneris,et al.  Human Histone Demethylase LSD1 Reads the Histone Code* , 2005, Journal of Biological Chemistry.

[109]  K. Morris,et al.  Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. , 2010, Current opinion in molecular therapeutics.

[110]  D. Santi,et al.  Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Antoine H. F. M. Peters,et al.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription , 2005, Nature.

[112]  Ming-Ming Zhou,et al.  Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. , 2005, Journal of the American Chemical Society.

[113]  R. Kingston,et al.  WDR5 Interacts with Mixed Lineage Leukemia (MLL) Protein via the Histone H3-binding Pocket* , 2008, Journal of Biological Chemistry.

[114]  Anton Simeonov,et al.  Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. , 2009, Journal of medicinal chemistry.

[115]  Tim J. Wigle,et al.  Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins , 2010, Journal of biomolecular screening.

[116]  K. Helin,et al.  Histone methyltransferases in cancer. , 2010, Seminars in cell & developmental biology.

[117]  T. Ahrens,et al.  Efficient Hit-Finding Approaches for Histone Methyltransferases , 2012, Journal of biomolecular screening.

[118]  Bing Li,et al.  Readers of histone modifications , 2011, Cell Research.

[119]  A. Jadhav,et al.  Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors , 2010, PloS one.

[120]  R. Schneider,et al.  Chatting histone modifications in mammals. , 2010, Briefings in functional genomics.

[121]  Shiv k. Sharma,et al.  (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.

[122]  Ming-Ming Zhou,et al.  Mechanism and Regulation of Acetylated Histone Binding by the Tandem PHD Finger of DPF3b , 2010, Nature.

[123]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[124]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[125]  J. Beutler,et al.  Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay , 2010, Journal of biomedicine & biotechnology.

[126]  N. Goodey,et al.  Allosteric regulation and catalysis emerge via a common route. , 2008, Nature chemical biology.

[127]  B. Strahl,et al.  Influence of Combinatorial Histone Modifications on Antibody and Effector Protein Recognition , 2011, Current Biology.

[128]  Jon R. Wilson,et al.  Characterization of a Novel WDR5-binding Site That Recruits RbBP5 through a Conserved Motif to Enhance Methylation of Histone H3 Lysine 4 by Mixed Lineage Leukemia Protein-1* , 2010, The Journal of Biological Chemistry.

[129]  Peter A. Jones,et al.  Epigenetic Modifications as Therapeutic Targets , 2010, Nature Biotechnology.

[130]  H. Haisma,et al.  Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation. , 2011, Drug discovery today.

[131]  S. Frye,et al.  Epigenetics: Tools and Technologies. , 2010, Drug discovery today. Technologies.

[132]  S. Schreiber,et al.  Identification of a Class of Small Molecule Inhibitors of the Sirtuin Family of NAD-dependent Deacetylases by Phenotypic Screening* , 2001, The Journal of Biological Chemistry.

[133]  Akinori Sarai,et al.  ProTherm and ProNIT: thermodynamic databases for proteins and protein–nucleic acid interactions , 2005, Nucleic Acids Res..

[134]  W-S Xu,et al.  Histone deacetylase inhibitors: Potential in cancer therapy , 2009, Journal of cellular biochemistry.

[135]  Ramars Amanchy,et al.  Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC). , 2005, Journal of proteome research.

[136]  T. Umehara,et al.  Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. , 2011, Chemistry & biology.

[137]  Anton Simeonov,et al.  Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. , 2010, Journal of medicinal chemistry.

[138]  U. Oppermann,et al.  Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. , 2008, Journal of medicinal chemistry.

[139]  Craig W Lindsley,et al.  Allosteric modulation of kinases and GPCRs: design principles and structural diversity. , 2008, Current opinion in chemical biology.

[140]  Sydney L. Stoops,et al.  Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. , 2011, ACS chemical biology.

[141]  Takayoshi Suzuki,et al.  Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.

[142]  M. Mann,et al.  Identifying and quantifying in vivo methylation sites by heavy methyl SILAC , 2004, Nature Methods.

[143]  C. Bronner,et al.  The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory. , 2007, Current medicinal chemistry.

[144]  Jian Jin,et al.  Small-molecule ligands of methyl-lysine binding proteins. , 2011, Journal of medicinal chemistry.

[145]  J. Chai,et al.  Structural basis of EZH2 recognition by EED. , 2007, Structure.

[146]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[147]  Randall W King,et al.  Small Molecule Regulators of Protein Arginine Methyltransferases* , 2004, Journal of Biological Chemistry.

[148]  Daniel Cressey,et al.  Traditional drug-discovery model ripe for reform , 2011, Nature.

[149]  Andrew J. Bannister,et al.  Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity , 2005, Molecular Cancer Therapeutics.